Sex and Gender Influences on Cancer Immunotherapy Response

Irelli, Azzurra; Sirufo, Maria Maddalena; D'Ugo, Carlo; Ginaldi, Lia; Martinis, Massimo De

doi:10.3390/biomedicines8070232

Cited by 85 publications

(84 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is in agreement with previous reports showing that female mice respond better to immunotherapy [ 36 ]. Gender influence on cancer immunotherapy has been recently reviewed by Irelli et al [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

Lasarte-Cía

Lozano

Cano

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background/Aim. Irreversible electroporation (IRE) showed promising results for small-size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long-term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c-di-GMP, a STING agonist, intratumorally. Materials and Methods. Intratumoral administration of c-di-GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L). Results. The combined therapy increased the number of tumor-infiltrating IFN-γ/TNF-α-producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c-di-GMP or IRE alone. Conclusion. These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

Lasarte-Cía

Lozano

Cano

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The risk of developing a second primary tumor varies across first tumor type; bladder cancer is most common as the first primary tumor, and lung cancer is the most common second primary tumor [ 5 ]. Certain patient populations, including male patients and patients with a history of smoking or alcoholism, are also at higher risk of developing MPMTs [ 2 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Gene expression profiling for the diagnosis of multiple primary malignant tumors

Zheng

Sun²,

Kuai

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background The incidence of multiple primary malignant tumors (MPMTs) is rising due to the development of screening technologies, significant treatment advances and increased aging of the population. For patients with a prior cancer history, identifying the tumor origin of the second malignant lesion has important prognostic and therapeutic implications and still represents a difficult problem in clinical practice. Methods In this study, we evaluated the performance of a 90-gene expression assay and explored its potential diagnostic utility for MPMTs across a broad spectrum of tumor types. Thirty-five MPMT patients from Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University and Fudan University Shanghai Cancer Center were enrolled; 73 MPMT specimens met all quality control criteria and were analyzed by the 90-gene expression assay. Results For each clinical specimen, the tumor type predicted by the 90-gene expression assay was compared with its pathological diagnosis, with an overall accuracy of 93.2% (68 of 73, 95% confidence interval 0.84–0.97). For histopathological subgroup analysis, the 90-gene expression assay achieved an overall accuracy of 95.0% (38 of 40; 95% CI 0.82–0.99) for well-moderately differentiated tumors and 92.0% (23 of 25; 95% CI 0.82–0.99) for poorly or undifferentiated tumors, with no statistically significant difference (p-value > 0.5). For squamous cell carcinoma specimens, the overall accuracy of gene expression assay also reached 87.5% (7 of 8; 95% CI 0.47–0.99) for identifying the tumor origins. Conclusions The 90-gene expression assay provides flexibility and accuracy in identifying the tumor origin of MPMTs. Future incorporation of the 90-gene expression assay in pathological diagnosis will assist oncologists in applying precise treatments, leading to improved care and outcomes for MPMT patients.

show abstract

“…The indication for systemic adjuvant therapy is decided on the basis of the biological characteristics of the tumor (the histological type, presence or absence of ductal carcinoma in situ, grade, Ki67, presence of peritumor vascular invasion, receptors for estrogen (ER), receptors for progesterone (PR), human epidermal growth factor receptor 2 (HER2) status, the number of regional lymph nodes involved, dimensions) and the patient’s clinical characteristics (age, performance status, comorbidity), with the help of scales such as Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Cumulative Illness Rating Scale (CIRS) and, considering the toxicities of the proposed therapy, the patient’s life expectancy, as well as her preferences [ 9 , 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management

Irelli

Sirufo

Quaglione³

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

We report the case of a 49-year-old woman diagnosed with a rare histotype of early breast cancer (BC), invasive ductal carcinoma with osteoclast-like giant cells (OGCs), from the perspective of gene profile analysis tests. The patient underwent a quadrantectomy of the right breast with removal of 2 cm neoplastic nodule and three ipsilateral sentinel lymph nodes. The Oncotype Dx gave a recurrence score (RS) of 23, and taking into account the patient’s age, an RS of 23 corresponds to a chemotherapy benefit of 6.5%. After a multidisciplinary collegial discussion, and in consideration of the patient’s age, the absence of comorbidity, the premenopausal state, the rare histotype and the Oncotype Dx report, the patient was offered adjuvant chemotherapy treatment followed by hormone therapy. This case may be an example of the utility of integrating gene expression profiling tests into clinical practice in the adjuvant treatment decision of a rare histotype BC. The Oncotype Dx test required to supplement the histological examination made us opt for the proposal of a combined treatment of adjuvant chemotherapy followed by adjuvant hormone therapy. It demonstrates the importance of considering molecular tests and, in particular, the Oncotype Dx, in estimating the risk of disease recovery at 10 years in order to identify patients who benefit from hormone therapy alone versus those who benefit from the addition of chemotherapy, all with a view toward patient-centered oncology. Here, we discuss the possible validity and limitations of the Oncotype Dx in a rare luminal A-like histotype with high infiltrate of stromal/inflammatory cells.

show abstract

Sex and Gender Influences on Cancer Immunotherapy Response

Cited by 85 publications

References 150 publications

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

Gene expression profiling for the diagnosis of multiple primary malignant tumors

Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management

Contact Info

Product

Resources

About